Carisma Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Good afternoon, everyone, and thank you for joining me at the fourth day of the Needham Healthcare Conference. My name is Gil Blum and I am a senior biotech analyst here at Needham & Company, and I cover the immuno-oncology subsector. It is my pleasure to have with me today, Steven Kelly, the President and CEO of Carisma. (Conference Instructions) And with that, Steven, please go ahead.
Great. Thanks, Gil. Really appreciate the opportunity to be at your conference and appreciate the opportunity to talk for a few minutes about Carisma and give you a flavor of what we're working on.
So Carisma is the world's leader in engineered myeloid cells. We have a really exciting platform. We have a pipeline of potential products, and we have a regular cadence of value inflection points as we as we look forward.
Our cell therapy platform really is a proprietary platform, takes all the traditional adoptive cell therapy tools and applies them with a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
